2023-01-25 22:30:00

Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to

Logo Benzinga
Benzinga
By Globe Newswire

Paris and Stockholm January 25, 2023 Pivotal study data published in continues to highlight the efficacy, safety, and pharmacokinetic profile of efanesoctocog alfa, an investigational treatment for hemophilia A. These data demonstrate that efanesoctocog alfa delivered normal to near-normal factor activity levels (>40%) for the majority of the week with once-weekly dosing. Efanesoctocog alfa is currently under priority review by the United States Food and Drug Administration (FDA) and the target action date for the decision is February 28, 2023.

Hemophilia A is a rare, lifelong condition in which the ability of a person's blood to clot properly is impaired, leading to excessive bleeds that can result in joint damage and chronic pain, and potentially impact their quality of life. The severity of hemophilia is determined by the level of clotting factor activity in a person's blood.

Investigator of the XTEND-1 Clinical Trial and Associate Professor at Michigan Medicine

The data from the pivotal XTEND-1 Phase 3 study published in show that efanesoctocog alfa met primary and key secondary endpoints, demonstrating clinically meaningful prevention of bleeds and superior bleed protection compared to prior factor VIII prophylaxis based on an intra-patient comparison. Treatment with efanesoctocog alfa prophylaxis resulted in significant and clinically meaningful improvements in physical health, pain, and joint health. Key results include:

Continue read on benzinga.com

Logo GlobeNewswire
SciencePress Release2023-01-25 22:30:00
NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A P...

Logo PR Newswire
HealthPress Release2023-01-25 11:15:00
Collaboration seeks to improve outcomes for patients with EGFR-positive non-small cell lung cancer WASHINGTON, Jan. 25, 2023 /PRNewswire/ -- LUNGevity...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:00:00
Topline results expected in first half of 2023 Trial sites open in Australia and United Kingdom WATERTOWN, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Eloxx...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:37:00
Nes-Ziona, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 14:24:00
Company's mobile-first platform empowers members of Northwell's Business Enterprise Resource Groups with tailored approaches to caregiving, training and...

Logo GlobeNewswire
SciencePress Release2023-01-25 21:05:00
CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3...

Logo PR Newswire
HealthPress Release2023-01-25 13:27:00
Patient Recruitment Underway NEW YORK, Jan. 25, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company,...

Logo U.S. News & World Report
PoliticsBy Health Day2023-01-25 12:37:00
By Cara Murez HealthDay Reporter WEDNESDAY, Jan. 25, 2023 (HealthDay News) -- Send yourself some love this Valentine's Day by setting a reminder to start...

Logo PR Newswire
HealthPress Release2023-01-25 12:30:00
Strong enrollment in Phase 3 trial demonstrates continued execution Interim analysis expected in 2Q 2023 BERWYN, Pa., Jan. 25, 2023 /PRNewswire/ -- Annovis...

Logo GlobeNewswire
SciencePress Release2023-01-25 21:05:00
LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3...

Logo Daily Mail
HealthBy Kate Pickles2023-01-25 12:09:36
A new drug is set to transform the lives of thousands of migraine sufferers after it was approved for use on the NHS. The National Institute for Health and...

Logo GlobeNewswire
SciencePress Release2023-01-25 21:01:00
Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:00:00
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage...

Logo Nasdaq
Business / FinanceBy Rtt News2023-01-25 13:14:19
(RTTNews) - Tango Therapeutics, Inc. (TNGX) Wednesday announced FDA clearance for its Investigational New Drug or IND application for TNG462, a...

Logo Daily Mail
HealthBy Emily Stearn2023-01-25 14:00:45
Another round of Covid booster jabs should be dished out this autumn, the Government's scientific advisers said today. Health chiefs also called for those...

Logo Benzinga
Business / FinanceBy Benzinga Insights2023-01-25 19:01:26
Eastern Bankshares EBC is set to give its latest quarterly earnings report on Thursday, 2023-01-26. Here's what investors need to know before the...

Logo PR Newswire
HealthPress Release2023-01-25 16:26:00
Policy-minded health care providers band together to support patients with rare, chronic condition called IgG4-RD WASHINGTON, Jan. 25, 2023 /PRNewswire/ -- A...

Logo PR Newswire
HealthPress Release2023-01-25 08:30:00
Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor...

Logo PR Newswire
TechnologyPress Release2023-01-25 15:00:00
PlumCare RWE and Lifebit enter a three-year partnership to support Greece's pioneering national newborn genomic sequencing program, BeginNGS. Researchers...

Logo PR Newswire
HealthPress Release2023-01-25 13:17:00
– ODACTRA is now indicated to treat house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, in persons 12 through 17 years of age,...